BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have been given a consensus rating of “Moderate Buy” by the twenty-four analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $89.17.

Several research analysts recently commented on the company. Weiss Ratings cut BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 18th. William Blair raised shares of BioMarin Pharmaceutical to a “hold” rating in a research report on Wednesday, September 23rd. Piper Sandler raised their target price on shares of BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, September 1st. Citigroup raised their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $60.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, September 10th.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN opened at $57.54 on Thursday. The firm’s 50 day moving average is $64.07 and its 200-day moving average is $58.66. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $11.14 billion, a PE ratio of 155.51, a price-to-earnings-growth ratio of 0.41 and a beta of 0.22. BioMarin Pharmaceutical has a 12-month low of $49.26 and a 12-month high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter in the prior year, the company posted $1.44 earnings per share. The firm’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts anticipate that BioMarin Pharmaceutical will post 4.1 earnings per share for the current fiscal year.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the stock. First Financial Bank Trust Division bought a new position in BioMarin Pharmaceutical in the 3rd quarter valued at about $1,945,000. Sequoia Financial Advisors LLC grew its position in shares of BioMarin Pharmaceutical by 70.8% in the second quarter. Sequoia Financial Advisors LLC now owns 12,796 shares of the biotechnology company’s stock valued at $732,000 after purchasing an additional 5,305 shares during the last quarter. NewEdge Advisors LLC increased its stake in shares of BioMarin Pharmaceutical by 12.1% during the second quarter. NewEdge Advisors LLC now owns 27,287 shares of the biotechnology company’s stock worth $1,561,000 after purchasing an additional 2,936 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 187 shares during the period. Finally, Corient Private Wealth LP lifted its holdings in BioMarin Pharmaceutical by 485.0% during the 2nd quarter. Corient Private Wealth LP now owns 35,525 shares of the biotechnology company’s stock worth $2,033,000 after purchasing an additional 29,452 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.